Leerink Partnrs Issues Positive Outlook for Moderna Earnings

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for Moderna in a research report issued to clients and investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($3.60) for the quarter, up from their prior estimate of ($3.64). The consensus estimate for Moderna's current full-year earnings is ($9.61) per share. Leerink Partnrs also issued estimates for Moderna's Q2 2025 earnings at ($3.54) EPS, Q3 2025 earnings at ($1.88) EPS, Q4 2025 earnings at ($1.47) EPS, FY2025 earnings at ($10.46) EPS, FY2026 earnings at ($7.48) EPS and FY2027 earnings at ($4.86) EPS.

A number of other equities research analysts also recently commented on the company. Royal Bank of Canada reiterated a "sector perform" rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. UBS Group cut their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Thursday. Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $58.70.

Moderna Price Performance

Shares of Moderna stock traded up $0.41 on Friday, hitting $25.13. 6,858,667 shares of the company's stock traded hands, compared to its average volume of 7,287,020. The firm's 50-day moving average price is $30.84 and its two-hundred day moving average price is $39.49. The stock has a market capitalization of $9.72 billion, a PE ratio of -2.71 and a beta of 2.23. Moderna has a one year low of $23.15 and a one year high of $170.47.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MRNA. FMR LLC grew its holdings in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after purchasing an additional 1,282,469 shares during the period. Theleme Partners LLP boosted its stake in Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after purchasing an additional 72,028 shares during the period. Geode Capital Management LLC grew its holdings in Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after buying an additional 171,774 shares in the last quarter. Invesco Ltd. increased its position in Moderna by 24.3% during the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after buying an additional 979,858 shares during the period. Finally, Norges Bank acquired a new stake in shares of Moderna during the fourth quarter worth $163,833,000. Institutional investors and hedge funds own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.